Abstract: A process for producing a cyclic acetal is disclosed. According to the process, a formaldehyde source is combined with an aprotic compound and contacted with a heterogeneous catalyst which causes the formaldehyde source to convert into a cyclic acetal such as trioxane. The catalyst, for instance, may comprise a solid catalyst such as an ion exchange resin. In one embodiment, the process is used for converting anhydrous formaldehyde gas to trioxane. The anhydrous formaldehyde gas may be produced form an aqueous formaldehyde solution by an extractive distillation. The aprotic compound and the formaldehyde solution may be extracted from the reaction product and recycled into the process.

Abstract: A process for producing a cyclic acetal is disclosed. According to the process, a formaldehyde source is combined with an aprotic compound and contacted with a heterogeneous catalyst which causes the formaldehyde source to convert into a cyclic acetal such as trioxane. The catalyst, for instance, may comprise a solid catalyst such as an ion exchange resin. In one embodiment, the process is used for converting anhydrous formaldehyde gas to trioxane. The anhydrous formaldehyde gas may be produced form an aqueous formaldehyde solution by an extractive distillation. The aprotic compound and the formaldehyde solution may be extracted from the reaction product and recycled into the process.

Abstract: A method for formation of a semi-crystalline polyarylene sulfide is described. The method can include reaction of sulfur-containing monomer with a dihaloaromatic monomer in an organic amide solvent to form a polymer following by combination of the polymer with a crystallization solution. The crystallization solution is pre-heated and the mixture formed is slowly cooled to crystallize the polymer.

Abstract: A multi-stage process and system for formation of a polyarylene sulfide is described. The multi-stage process can include at least three separate formation stages that can take place in three different reactors. The first stage of the formation process can include reaction of an alkali metal sulfide with an organic amide solvent to form a complex including a hydrolysis product of the solvent and an alkali metal hydrogen sulfide. The second stage of the formation process can include reaction of the complex formed in the first stage with a dihaloaromatic monomer to form a prepolymer, and the third stage can include further polymerization of the prepolymer with additional monomers to form the final product.

Abstract: A method for formation of a semi-crystalline polyarylene sulfide is described. The method can include reaction of sulfur-containing monomer with a dihaloaromatic monomer in an organic amide solvent to form a polymer following by combination of the polymer with a crystallization solution. The crystallization solution is pre-heated and the mixture formed is slowly cooled to crystallize the polymer.

Abstract: A method for formation of a semi-crystalline polyarylene sulfide is described. The method can include reaction of sulfur-containing monomer with a dihaloaromatic monomer in an organic amide solvent to form a polymer following by combination of the polymer with a crystallization solution. The crystallization solution is pre-heated and the mixture formed is slowly cooled to crystallize the polymer.

Abstract: A method for formation of a semi-crystalline polyarylene sulfide is described. The method can include reaction of sulfur-containing monomer with a dihaloaromatic monomer in an organic amide solvent to form a polymer following by combination of the polymer with a crystallization solution. The crystallization solution is pre-heated and the mixture formed is slowly cooled to crystallize the polymer.

Abstract: A multi-stage process and system for formation of a polyarylene sulfide is described. The multi-stage process can include at least three separate formation stages that can take place in three different reactors. The first stage of the formation process can include reaction of an alkali metal sulfide with an organic amide solvent to form a complex including a hydrolysis product of the solvent and an alkali metal hydrogen sulfide. The second stage of the formation process can include reaction of the complex formed in the first stage with a dihaloaromatic monomer to form a prepolymer, and the third stage can include further polymerization of the prepolymer with additional monomers to form the final product.

Abstract: Systems and methods are provided for managing patients during pain management treatment that includes a server and a medical database including patient information associated with patients within a territory, the medical information including a status of each patient indicating a stage of treatment between a candidate for treatment stage, one or more pre-treatment stages, and one or more treatment stages. The system also includes team electronic devices communicating with the server to add and/or update information regarding patients in the medical database and/or synchronize local databases of the team electronic devices with the medical database.

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

Abstract: A computer system configured to retrieve a preboot image from a first remote location and execute the preboot image. The preboot image is configured to cause the computer system to detect a status indication associated with a previous boot attempt by the computer system, and, in response to the status indication indicating a local boot attempt state, to retrieve a first boot image from a second remote location and to boot the computer system using the first boot image.

Abstract: A process for preparing a finely divided preparation of a drug substance comprising wet milling a suspension of the drug substance in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising nylon, wherein the nylon comprises one or more internal lubricants results in finely divided preparations of a drug substance in which the level of grinding media contamination and process contamination are reduced.

Abstract: A pharmaceutical composition comprising a compound of formula (I) in particulate form, said composition having a particle size distribution such that the median value of the volume mean diameter is within the range of from 350 to 700 nm.

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.

Abstract: A computer system configured to retrieve a preboot image from a first remote location and execute the preboot image. The preboot image is configured to cause the computer system to detect a status indication associated with a previous boot attempt by the computer system, and, in response to the status indication indicating a local boot attempt state, to retrieve a first boot image from a second remote location and to boot the computer system using the first boot image.

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

Abstract: Pharmaceutical formulations of paroxetine are provided in which the paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or self-supporting solid solutions are shaped into solid dosage forms such as tablets or pellets. Also disclosed are novel liquid formulations in which a solubilising agent is used to solubilise paroxetine in oils and/or lipids, and methods of avoiding other paroxetine forms converting to the hemihydrate, by use of anhydrous or hydrophobic carriers or excipients.

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.